Dr. Simone Discusses the Precision Promise Trial in Pancreatic Cancer

May 23, 2018
Diane Simeone, MD

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

The Pancreatic Cancer Action Network has designed an adaptive clinical trial platform called Precision Promise. This trial will have multiple experimental arms within the platform, and every patient will be comprehensively studied before and on therapy with biopsies. Currently, there are 12 centers around the country who are a part of Precision Promise, Simeone says. Another 6 sites will be brought onboard.

The goal of this trial is to organize clinical trials for pancreatic cancer in a different way, Simeone says. Findings with hopefully determine why some approaches work and why others don’t, and then taking that knowledge to design better, more informed clinical trials.

Multiple pharmaceutical companies are involved in Precision Promise, allowing a variety of different agents to be evaluated simultaneously.


x